1
|
Vellas C, Dimeglio C, Joncour E, Staes L, Jamme T, Miedougé M, Da-Silva I, Porcheron M, Migueres M, Kamar N, Izopet J. Evaluation of two anti-SARS-CoV-2 antibody immunoassays for monitoring patients on pre-exposure prophylaxis. Diagn Microbiol Infect Dis 2023; 107:116071. [PMID: 37716217 DOI: 10.1016/j.diagmicrobio.2023.116071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 07/31/2023] [Accepted: 08/22/2023] [Indexed: 09/18/2023]
Abstract
Pre-exposure prophylaxis (PrEP) is crucial to prevent severe COVID-19 in immunocompromised patients. A reliable method is needed to quantify anti-SARS-CoV-2 antibody levels for personalized monitoring during PrEP. We measured the binding antibody concentrations of 63 immunocompromised patients receiving 300mg or 600mg tixagevimab/cilgavimab on PrEP day and twice during the following 3 months. All blood samples were tested using the Abbott anti-SARS-CoV-2 IgG II Quant assay, the Roche Elecsys anti-SARS-CoV-2 S assay, and live virus-based neutralization assays. The results of the two immunoassays were correlated on day 0, 1 month, and 3 months post-PrEP. Passing-Bablok regression demonstrated higher anti-S concentration values measured with the Roche immunoassay compared to those measured with the Abbott immunoassay. Antibody concentrations were higher after 600 mg tixagevimab/cilgavimab prophylaxis than after 300 mg. The neutralizing antibody titers obtained using the omicron BA.5 and BA.2.75 strains were low. Both automated immunoassays are suitable for monitoring immunocompromised patients on PrEP.
Collapse
Affiliation(s)
- Camille Vellas
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France.
| | - Chloé Dimeglio
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| | - Emma Joncour
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| | - Laetitia Staes
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| | - Thibaut Jamme
- CHU de Toulouse, Laboratorie de Biochimie, Toulouse, France
| | | | | | | | - Marion Migueres
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| | - Nassim Kamar
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Département de Néphrologie, Dialyse et Transplantation d'Organes, Toulouse, France
| | - Jacques Izopet
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| |
Collapse
|
2
|
Dimeglio C, Da-Silva I, Porcheron M, Panero MP, Staes L, Trémeaux P, Villars H, Izopet J. Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population. Vaccines (Basel) 2023; 11:1095. [PMID: 37376484 DOI: 10.3390/vaccines11061095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 06/03/2023] [Accepted: 06/08/2023] [Indexed: 06/29/2023] Open
Abstract
The vaccines presently available are less effective in older people due to senescence of their immune systems. We measured the antibody responses of 42 adults living in nursing homes after the third and the fourth doses of an mRNA vaccine and found that the strain (BA.2 and BA.2.75: from 64 to 128, BA.5: from 16 to 32, BQ.1.1: from 16 to 64 among the uninfected) influenced the effect of the fourth dose of vaccine on neutralizing antibodies. The fourth dose also increased binding antibodies (from 1036 BAU/mL to 5371 BAU/mL among the uninfected, from 3700 BAU/mL to 6773 BAU/mL among the BA.5 infected). This effect was less significant than that of the third dose of vaccine for both neutralizing (BA.2: from 8 to 128, BA.5: from 2 to 16, BA.2.75: from 8 to 64, BQ.1.1: from 2 to 16) and binding antibodies (from 139.8 BAU/mL to 2293 BAU/mL). However, the fourth dose attained the 5000 BAU/mL threshold conferring approximately 80% protection against a SARS-CoV-2 BA.2 infection in most individuals, unlike the third.
Collapse
Affiliation(s)
- Chloé Dimeglio
- Virology Laboratory, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France
- Inserm UMR 1291-CNRS UMR 5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), 31300 Toulouse, France
| | - Isabelle Da-Silva
- Virology Laboratory, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France
| | - Marion Porcheron
- Virology Laboratory, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France
| | | | - Laetitia Staes
- Virology Laboratory, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France
| | - Pauline Trémeaux
- Virology Laboratory, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France
- Inserm UMR 1291-CNRS UMR 5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), 31300 Toulouse, France
| | - Hélène Villars
- Inserm UMR 1295: Center for Research in Population Health (CERPOP), Department of Epidemiology and Public Health, Toulouse, University of Toulouse III, 31073 Toulouse, France
- Geriatric Department, CHU Toulouse, Toulouse University Hospital, Hôpital Purpan Pavillon Leriche, 31300 Toulouse, France
| | - Jacques Izopet
- Virology Laboratory, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France
- Inserm UMR 1291-CNRS UMR 5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), 31300 Toulouse, France
| |
Collapse
|
3
|
Migueres M, Chapuy‐Regaud S, Miédougé M, Jamme T, Lougarre C, Da Silva I, Pucelle M, Staes L, Porcheron M, Diméglio C, Izopet J. Current immunoassays and detection of antibodies elicited by Omicron SARS-CoV-2 infection. J Med Virol 2023; 95:e28200. [PMID: 36207814 PMCID: PMC9874650 DOI: 10.1002/jmv.28200] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 09/12/2022] [Accepted: 10/03/2022] [Indexed: 01/27/2023]
Abstract
The present study aimed to determine whether current commercial immunoassays are adequate for detecting anti-Omicron antibodies. We analyzed the anti-SARS-CoV-2 antibody response of 23 unvaccinated individuals 1-2 months after an Omicron infection. All blood samples were tested with a live virus neutralization assay using a clinical Omicron BA.1 strain and four commercial SARS-CoV-2 immunoassays. We assessed three anti-Spike immunoassays (SARS-CoV-2 IgG II Quant [Abbott S], Wantaï anti-SARS-CoV-2 antibody ELISA [Wantaï], Elecsys Anti-SARS-CoV-2 S assay [Roche]) and one anti-Nucleocapsid immunoassay (Abbott SARS-CoV-2 IgG assay [Abbott N]). Omicron neutralizing antibodies were detected in all samples with the live virus neutralization assay. The detection rate of the Abbott S, Wantai, Roche, and Abbott N immunoassays were 65.2%, 69.6%, 86.9%, and 91.3%, respectively. The sensitivities of Abbott S and Wantai immunoassays were significantly lower than that of the live virus neutralization assay (p = 0.004, p = 0.009; Fisher's exact test). Antibody concentrations obtained with anti-S immunoassays were correlated with Omicron neutralizing antibody concentrations. These data provide clinical evidence of the loss of performance of some commercial immunoassays to detect antibodies elicited by Omicron infections. It highlights the need to optimize these assays by adapting antigens to the circulating SARS-CoV-2 strains.
Collapse
Affiliation(s)
- Marion Migueres
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance,Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 ‐ CNRS UMR5051ToulouseFrance,Université Toulouse III Paul‐SabatierToulouseFrance
| | - Sabine Chapuy‐Regaud
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance,Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 ‐ CNRS UMR5051ToulouseFrance,Université Toulouse III Paul‐SabatierToulouseFrance
| | - Marcel Miédougé
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Thibaut Jamme
- Laboratoire de Biochimie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | | | - Isabelle Da Silva
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Mélanie Pucelle
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Laetitia Staes
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Marion Porcheron
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Chloé Diméglio
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance,Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 ‐ CNRS UMR5051ToulouseFrance,Université Toulouse III Paul‐SabatierToulouseFrance
| | - Jacques Izopet
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance,Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 ‐ CNRS UMR5051ToulouseFrance,Université Toulouse III Paul‐SabatierToulouseFrance
| |
Collapse
|
4
|
Abravanel F, Marion O, Del Bello A, Beunon T, Romieu-Mourez R, Couat C, Pucelle M, Staes L, Guitard J, Esposito L, Faguer S, Kamar N, Izopet J. Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. Vaccines (Basel) 2022; 10:vaccines10030354. [PMID: 35334985 PMCID: PMC8949272 DOI: 10.3390/vaccines10030354] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 02/19/2022] [Accepted: 02/21/2022] [Indexed: 02/04/2023] Open
Abstract
Background: Two doses of anti-SARS-CoV-2 mRNA-based vaccines are poorly immunogenic in solid organ transplant recipients (SOT). Methods: In total, 68 belatacept-treated SOT recipients followed at the Toulouse University Hospital were investigated. They were given three injections of the BNT162b2 mRNA COVID-19 vaccine. Their humoral response was assessed by determining anti-spike antibodies and neutralizing antibodies. The T-cell responses were assessed using an enzyme-linked immunospot assay that measured the interferon-γ produced by specific SARS-CoV-2 T-cells in a subgroup of 17 patients. Results: Only 23.5% of these patients developed a detectable anti-spike response. Moreover, the cellular and the humoral responses were well correlated. Patients with no humoral response were also without a detectable cellular response. Those belatacept-treated patients who developed an Anti-SARS-CoV-2 humoral response were younger, had been transplanted for longer, and had a higher lymphocyte count and a better glomerular filtration rate than those with no response. Finally, patients on tacrolimus plus belatacept produced a lower immune response. Conclusions: Belatacept-treated SOT recipients have a reduced immune response to anti-SARS-CoV-2 mRNA vaccination. The vaccine should be given quite separately from the belatacept infusion to improve immunogenicity. Studies to assess whether switching to another immunosuppressive regimen can improve the post-vaccination immune response would be useful.
Collapse
Affiliation(s)
- Florence Abravanel
- Laboratory of Virology, Toulouse Purpan University Hospital, 31073 Toulouse, France; (T.B.); (R.R.-M.); (M.P.); (L.S.); (J.I.)
- INFINITY—Inserm U1291-CNRS U5051, 31073 Toulouse, France; (O.M.); (N.K.)
- School of Medicine Rangueil, Paul Sabatier University, 31062 Toulouse, France; (A.D.B.); (S.F.)
- Correspondence: ; Tel.: +33-6-76-90-430
| | - Olivier Marion
- INFINITY—Inserm U1291-CNRS U5051, 31073 Toulouse, France; (O.M.); (N.K.)
- School of Medicine Rangueil, Paul Sabatier University, 31062 Toulouse, France; (A.D.B.); (S.F.)
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, 31073 Toulouse, France; (C.C.); (J.G.); (L.E.)
| | - Arnaud Del Bello
- School of Medicine Rangueil, Paul Sabatier University, 31062 Toulouse, France; (A.D.B.); (S.F.)
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, 31073 Toulouse, France; (C.C.); (J.G.); (L.E.)
| | - Thomas Beunon
- Laboratory of Virology, Toulouse Purpan University Hospital, 31073 Toulouse, France; (T.B.); (R.R.-M.); (M.P.); (L.S.); (J.I.)
| | - Raphaelle Romieu-Mourez
- Laboratory of Virology, Toulouse Purpan University Hospital, 31073 Toulouse, France; (T.B.); (R.R.-M.); (M.P.); (L.S.); (J.I.)
| | - Chloé Couat
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, 31073 Toulouse, France; (C.C.); (J.G.); (L.E.)
| | - Mélanie Pucelle
- Laboratory of Virology, Toulouse Purpan University Hospital, 31073 Toulouse, France; (T.B.); (R.R.-M.); (M.P.); (L.S.); (J.I.)
| | - Laetitia Staes
- Laboratory of Virology, Toulouse Purpan University Hospital, 31073 Toulouse, France; (T.B.); (R.R.-M.); (M.P.); (L.S.); (J.I.)
| | - Joelle Guitard
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, 31073 Toulouse, France; (C.C.); (J.G.); (L.E.)
| | - Laure Esposito
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, 31073 Toulouse, France; (C.C.); (J.G.); (L.E.)
| | - Stanislas Faguer
- School of Medicine Rangueil, Paul Sabatier University, 31062 Toulouse, France; (A.D.B.); (S.F.)
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, 31073 Toulouse, France; (C.C.); (J.G.); (L.E.)
| | - Nassim Kamar
- INFINITY—Inserm U1291-CNRS U5051, 31073 Toulouse, France; (O.M.); (N.K.)
- School of Medicine Rangueil, Paul Sabatier University, 31062 Toulouse, France; (A.D.B.); (S.F.)
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, 31073 Toulouse, France; (C.C.); (J.G.); (L.E.)
| | - Jacques Izopet
- Laboratory of Virology, Toulouse Purpan University Hospital, 31073 Toulouse, France; (T.B.); (R.R.-M.); (M.P.); (L.S.); (J.I.)
- INFINITY—Inserm U1291-CNRS U5051, 31073 Toulouse, France; (O.M.); (N.K.)
- School of Medicine Rangueil, Paul Sabatier University, 31062 Toulouse, France; (A.D.B.); (S.F.)
| |
Collapse
|